Clinical and immune profiling for cancer of unknown primary site

Clinical and immune profiling for cancer of unknown primary site

Abstract Background Immune checkpoint inhibitors (ICIs) confer a survival benefit in many cancer types. Given that the survival outcome for cancer of unknown primary site (CUP) remains poor, we investigated the potential of CUP for immunotherapy. Methods A total of 164 patients with CUP (favorable s...

Full description

Bibliographic Details
Main Authors: Koji Haratani, Hidetoshi Hayashi, Takayuki Takahama, Yasushi Nakamura, Shuta Tomida, Takeshi Yoshida, Yasutaka Chiba, Takahiro Sawada, Kazuko Sakai, Yoshihiko Fujita, Yosuke Togashi, Junko Tanizaki, Hisato Kawakami, Akihiko Ito, Kazuto Nishio, Kazuhiko Nakagawa
Format: Article
Language:English
Published: BMJ Publishing Group 2019-09-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Cancer of unknown primary site (CUP)
Gene expression
Immune profile
Immunotherapy
Immune checkpoint inhibitor
Online Access:http://link.springer.com/article/10.1186/s40425-019-0720-z

Internet

http://link.springer.com/article/10.1186/s40425-019-0720-z

Similar Items